116 related articles for article (PubMed ID: 8675231)
21. Immunological abnormalities in patients with chronic fatigue syndrome.
Tirelli U; Marotta G; Improta S; Pinto A
Scand J Immunol; 1994 Dec; 40(6):601-8. PubMed ID: 7997849
[TBL] [Abstract][Full Text] [Related]
22. Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activity.
Bolay H; Karabudak R; Aybay C; Candemir H; Varli K; Imir T; Kansu E
J Neuroimmunol; 1998 Mar; 82(2):109-15. PubMed ID: 9585806
[TBL] [Abstract][Full Text] [Related]
23. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
24. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
[TBL] [Abstract][Full Text] [Related]
25. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a.
Nortvedt MW; Riise T; Myhr KM; Nyland HI; Hanestad BR
Mult Scler; 1999 Oct; 5(5):317-22. PubMed ID: 10516774
[TBL] [Abstract][Full Text] [Related]
26. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C.
Malaponte G; Passero E; Leonardi S; Monte V; Lauria C; Mazzarino C; Sciotto A; Russo Mancuso G; Di Gregorio F; Musumeci S
Acta Haematol; 1997; 98(2):83-8. PubMed ID: 9286304
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
[TBL] [Abstract][Full Text] [Related]
28. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction.
Hassan IS; Bannister BA; Akbar A; Weir W; Bofill M
Clin Immunol Immunopathol; 1998 Apr; 87(1):60-7. PubMed ID: 9576011
[TBL] [Abstract][Full Text] [Related]
29. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome.
Ojo-Amaize EA; Conley EJ; Peter JB
Clin Infect Dis; 1994 Jan; 18 Suppl 1():S157-9. PubMed ID: 8148445
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J; Zeuzem S; Feinman SV; Heathcote EJ; Manns M; Yoshida EM; Swain MG; Gane E; Diago M; Revicki DA; Lin A; Wintfeld N; Green J
Pharmacoeconomics; 2003; 21(5):341-9. PubMed ID: 12627987
[TBL] [Abstract][Full Text] [Related]
31. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.
McDermott C; Richards SC; Thomas PW; Montgomery J; Lewith G
QJM; 2006 Jul; 99(7):461-8. PubMed ID: 16809351
[TBL] [Abstract][Full Text] [Related]
32. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
Lebow LT; Jewett A; Bonavida B
J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
[TBL] [Abstract][Full Text] [Related]
33. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
[TBL] [Abstract][Full Text] [Related]
34. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
[TBL] [Abstract][Full Text] [Related]
36. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation.
Peakman M; Deale A; Field R; Mahalingam M; Wessely S
Clin Immunol Immunopathol; 1997 Jan; 82(1):83-91. PubMed ID: 9000046
[TBL] [Abstract][Full Text] [Related]
37. [The interrelation of the expression of HLA class I and II proteins and of the costimulatory proteins CD11a/CD18 and CD16 with the lytic activity of resting and activated natural killer lymphocytes].
Musatov MI; Petrova ED; Konenkov VI
Tsitologiia; 1997; 39(7):617-28. PubMed ID: 9490502
[TBL] [Abstract][Full Text] [Related]
38. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
[TBL] [Abstract][Full Text] [Related]
39. Immunologic abnormalities associated with chronic fatigue syndrome.
Barker E; Fujimura SF; Fadem MB; Landay AL; Levy JA
Clin Infect Dis; 1994 Jan; 18 Suppl 1():S136-41. PubMed ID: 8148441
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection.
Tang TJ; Kwekkeboom J; Mancham S; Binda RS; de Man RA; Schalm SW; Kusters JG; Janssen HL
J Hepatol; 2005 Jul; 43(1):45-52. PubMed ID: 15893402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
